Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
10.71B
Market cap10.71B
Price-Earnings ratio
-10.67
Price-Earnings ratio-10.67
Dividend yield
Dividend yield
Average volume
1.59M
Average volume1.59M
High today
$77.99
High today$77.99
Low today
$75.81
Low today$75.81
Open price
$77.31
Open price$77.31
Volume
1.20M
Volume1.20M
52 Week high
$88.31
52 Week high$88.31
52 Week low
$35.22
52 Week low$35.22

Stock Snapshot

With a market cap of 10.71B, Cytokinetics(CYTK) trades at $77.09. The stock has a price-to-earnings ratio of -10.67.

During the trading session on 2026-08-25, Cytokinetics(CYTK) shares reached a daily high of $77.99 and a low of $75.81. At a current price of $77.09, the stock is +1.7% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 1.2M, compared to an average daily volume of 1.59M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $35.22.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $35.22.

CYTK News

Simply Wall St 2d
Cytokinetics Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data

Cytokinetics (CYTK) has drawn fresh attention after disclosing that it will present favorable topline results from its ACACIA-HCM Phase 3 aficamten trial at the...

Cytokinetics Could Be 29% Undervalued Following Favorable Phase 3 Aficamten Data
Nasdaq 2d
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 Key Points The transaction involved the disposal of 7,500 shares. The disposi...

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
TipRanks 6d
Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on August 18, 2026. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with Ti...

Analyst ratings

91%

of 23 ratings
Buy
91.3%
Hold
8.7%
Sell
0%

More CYTK News

TipRanks 6d
Cytokinetics Earnings Call Highlights MYQORZO Surge

Cytokinetics ((CYTK)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful investing...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.